Acceleron Pharma Company Profile (NASDAQ:XLRN)

About Acceleron Pharma

Acceleron Pharma logoAcceleron Pharma Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutic candidates that are based on mechanisms, which the human body uses to regulate the growth and repair of its cells and tissues. Its therapeutic candidates are used to treat serious and rare diseases. The Company's pipeline includes Luspatercept, Sotatercept, Dalantercept, ACE-083, ACE-2494, ACE-1332, ACE-3891, ACE-2798, ACE-2536 and ACE-2395. Luspatercept promotes red blood cell production. It is developing Sotatercept for the treatment of chronic kidney disease. Dalantercept treats cancers by inhibiting blood vessel formation by inhibiting signaling through the activin receptor-like kinase (ALK) 1 receptor. ACE-083 is for the treatment of focal muscle disorders. ACE-2494 is designed to treat systemic muscle disorders. ACE-3891, ACE-1332, ACE-2798, ACE-2536 and ACE-2395 are in preclinical stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: XLRN
  • CUSIP:
Key Metrics:
  • Previous Close: $26.47
  • 50 Day Moving Average: $25.22
  • 200 Day Moving Average: $30.36
  • 52-Week Range: $22.67 - $41.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -13.55
  • P/E Growth: 0.00
  • Market Cap: $961.39M
  • Outstanding Shares: 37,746,000
  • Beta: 1.73
  • Net Margins: -229.77%
  • Return on Equity: -30.75%
  • Return on Assets: -26.64%
  • Current Ratio: 8.96%
  • Quick Ratio: 8.96%
Additional Links:
Companies Related to Acceleron Pharma:

Analyst Ratings

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (?)
Ratings Breakdown: 1 Hold Rating, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.91)
Consensus Price Target: $46.80 (85.71% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
DateFirmActionRatingPrice TargetDetails
12/25/2016Oppenheimer Holdings, Inc.Initiated CoverageBuy$44.00View Rating Details
12/12/2016CannInitiated CoverageOutperform$367.30 -> $44.00View Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00View Rating Details
9/29/2016Citigroup Inc.Initiated CoverageNeutral$40.00View Rating Details
9/28/2016FBR & CoReiterated RatingBuyView Rating Details
9/28/2016Credit Suisse GroupReiterated RatingBuy$42.00View Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00View Rating Details
8/5/2016Morgan StanleyReiterated RatingBuy$58.00View Rating Details
6/13/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $42.00View Rating Details
6/10/2016Piper Jaffray CompaniesReiterated RatingBuyView Rating Details
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00View Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralView Rating Details
3/3/2015JMP SecuritiesBoost Price TargetMarket Outperform$52.00 -> $58.00View Rating Details
(Data available from 2/23/2015 forward)


Earnings History for Acceleron Pharma (NASDAQ:XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017($0.55)N/AView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)ViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$3.80 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)ViewN/AView Earnings Details
8/12/2014($0.55)($0.54)ViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
Current Year EPS Consensus Estimate: $-1.59 EPS
Next Year EPS Consensus Estimate: $-1.86 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.43)($0.10)($0.27)
Q2 20163($0.59)($0.45)($0.52)
Q3 20162($0.63)($0.54)($0.59)
Q4 20162($0.59)($0.43)($0.51)
Q1 20172($0.60)($0.43)($0.52)
Q2 20173($0.66)($0.44)($0.57)
Q3 20172($0.75)($0.46)($0.61)
Q4 20172($0.81)($0.55)($0.68)
(Data provided by Zacks Investment Research)


Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Acceleron Pharma (NASDAQ:XLRN)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 82.57%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.00View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.00View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.00View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.88View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.12View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.60View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.32View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.00View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.00View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
News IconInvestor Focus: Watching Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) - Baldwin Journal (NASDAQ:XLRN) - February 23 at 3:57 AM logoAcceleron Pharma to Webcast Conference Call of Fourth Quarter and Year Ended 2016 Financial Results on March 1, 2017 (NASDAQ:XLRN) - February 22 at 10:54 AM
News IconTrading Watch: Checking in on Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) - BVN (NASDAQ:XLRN) - February 21 at 4:18 PM
News IconStock Corner: Tracking Metrics for Acceleron Pharma Inc. (NASDAQ:XLRN) - Rives Journal (NASDAQ:XLRN) - February 18 at 11:12 AM logoAcceleron Pharma Inc. (NASDAQ:XLRN) EPS Target At $-0.61 - Investor Newswire (NASDAQ:XLRN) - February 17 at 5:18 PM
News IconIs The Sell-Side Predicting That Acceleron Pharma Inc. (NASDAQ:XLRN) Will Move Higher? - Winfield Review (NASDAQ:XLRN) - February 17 at 8:19 AM logoAcceleron to Participate in Two Healthcare Investor Conferences in February (NASDAQ:XLRN) - February 1 at 7:33 AM
News IconEarnings in Full Force, Analysts Take Aim at Acceleron Pharma Inc. (NASDAQ:XLRN) - Wall Street Beacon (NASDAQ:XLRN) - January 27 at 6:52 AM
News IconChecking the Charts for Acceleron Pharma Inc. (XLRN) - Market Point (NASDAQ:XLRN) - January 27 at 6:52 AM
News IconAcceleron Pharma Inc XLRN Pharmaceuticals Healthcare Deals and Alliances Profile Prices from USD $250 (NASDAQ:XLRN) - January 18 at 5:56 AM
News IconAverage Directional Index in Review for Acceleron Pharma Inc. (XLRN) - Springdale Times (NASDAQ:XLRN) - January 17 at 8:41 AM
News IconWill The Needle Move For Acceleron Pharma Inc. (NASDAQ:XLRN) Shares This Earnings Season? - Wall Street Beacon (NASDAQ:XLRN) - January 13 at 7:18 AM logoACCELERON PHARMA INC. (NASDAQ:XLRN) Files An 8-K Regulation FD Disclosure (NASDAQ:XLRN) - January 10 at 4:25 PM logoAcceleron Pharma (XLRN) presents at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:XLRN) - January 10 at 4:25 PM logoAcceleron Pharma Inc. (NASDAQ:XLRN) Records An Impact Score Of 75 - Investor Newswire (NASDAQ:XLRN) - January 9 at 8:24 PM
News IconTop Stock With Upside & Growth Potential: Acceleron Pharma Inc. (NASDAQ:XLRN) - Prospect Journal (NASDAQ:XLRN) - January 9 at 3:24 PM logoACCELERON PHARMA INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:XLRN) - January 9 at 3:24 PM logoInsider Trading Activity Acceleron Pharma Inc. (NASDAQ:XLRN) – CFO Sold 1700 shares of Stock - Market Exclusive (NASDAQ:XLRN) - January 9 at 4:52 AM
News IconHome Business Acceleron Pharma Inc. (XLRN) stock slides, “Buy” rating reiterated at Credit Suisse... - BNB Daily (blog) (NASDAQ:XLRN) - January 9 at 4:52 AM
News IconRegulatory Insider Filing: Acceleron Pharma Inc (NASDAQ:XLRN)’s EVP & Chief Medical Officer Matthew Sherman Sold 2,000 Shares (NASDAQ:XLRN) - January 7 at 6:33 AM logoAcceleron Outlines Corporate Goals and Priorities for 2017 (NASDAQ:XLRN) - January 7 at 6:33 AM
News IconDirector of Acceleron Pharma Inc (NASDAQ:XLRN), Zakrzewski Joseph S, buys 4,000 shares worth $102,000 (NASDAQ:XLRN) - January 4 at 7:50 AM logoAcceleron to Webcast Presentation at 35th Annual J.P. Morgan Healthcare Conference (NASDAQ:XLRN) - January 4 at 7:50 AM
News IconCan This Stock Hit on All Cylinders And Achieve Projections: Acceleron Pharma Inc. (NASDAQ:XLRN) - Prospect Journal (NASDAQ:XLRN) - December 26 at 7:50 PM logoAcceleron Pharma (XLRN) Says First Patient Treated in Phase 2 Trial of ACE-083 in FSHD (NASDAQ:XLRN) - December 23 at 5:14 AM logo5:03 pm Acceleron Pharma treats the first patient in a Phase 2 clinical trial of ACE-083 for the treatment of patients with facioscapulohumeral muscular dystrophy (NASDAQ:XLRN) - December 23 at 5:14 AM logoAcceleron Announces First Patient Treated in Phase 2 Trial of ACE-083 in Facioscapulohumeral Muscular Dystrophy (NASDAQ:XLRN) - December 23 at 5:14 AM
News IconKeeping Tabs on Levels for Acceleron Pharma Inc. (NASDAQ:XLRN) - The Business Journal (NASDAQ:XLRN) - December 16 at 6:36 AM
News IconTechnical Study: Following Indicators for Acceleron Pharma Inc. (XLRN) - StockTalk Daily (NASDAQ:XLRN) - December 14 at 3:51 PM
News IconStock Spotlight: Zooming in on Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) - The Business Journal (NASDAQ:XLRN) - December 14 at 8:38 AM logoCoverage initiated on Acceleron Pharma by Oppenheimer (NASDAQ:XLRN) - December 14 at 8:38 AM
News IconTechnical Monitor: Checking on Current Levels for Acceleron Pharma Inc. (XLRN) - StockTalk Daily (NASDAQ:XLRN) - December 11 at 8:05 AM
News IconInvestor Scope: Taking a Closer Look at Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) - Marion Business Daily (NASDAQ:XLRN) - December 8 at 10:01 AM logoACCELERON PHARMA INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:XLRN) - December 7 at 11:29 PM
News IconInvestors are Watching Shares of Acceleron Pharma Inc. (NASDAQ:XLRN) - Marion Business Daily (NASDAQ:XLRN) - December 5 at 7:56 PM logoAcceleron and Celgene Announce Updated Results from Phase 2 Studies of Luspatercept in Beta-Thalassemia Presented at the 58th Annual Meeting of the American Society of Hematology (NASDAQ:XLRN) - December 5 at 7:56 PM
News IconValue Focus: Following the Numbers for Acceleron Pharma Inc. (NASDAQ:XLRN) - The Business Journal (NASDAQ:XLRN) - December 5 at 8:05 AM logoCelgene (CELG), Acceleron Pharma (XLRN) Announce Updated Data from Luspatercept Phase 2 in MDS - (NASDAQ:XLRN) - December 5 at 8:05 AM logo2:28 am Acceleron Pharma and Celgene report updated results from ongoing Phase 2 studies of Luspatercept; Preliminary data shows increases hemoglobin and achieves durable transfusion independence (NASDAQ:XLRN) - December 5 at 8:05 AM logoAcceleron and Celgene Announce Preliminary Results from an Investigator Initiated Phase 2 Study of Sotatercept in Myelofibrosis at the 58th Annual Meeting of the American Society of Hematology (NASDAQ:XLRN) - December 5 at 8:05 AM logoAcceleron Pharma Inc Conference Call to Review Data Presented at American Society of Hematology Annual Meeting scheduled for 9:00 am ET today (NASDAQ:XLRN) - December 5 at 8:05 AM
News IconAcceleron & Celgene Announce Updated Results from Ongoing Phase 2 Studies of Luspatercept in Myelodysplastic Syndromes at the... (NASDAQ:XLRN) - December 4 at 7:34 PM logoAcceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : December 1, 2016 (NASDAQ:XLRN) - December 3 at 8:50 AM logoETFs with exposure to Acceleron Pharma, Inc. : December 2, 2016 (NASDAQ:XLRN) - December 2 at 8:56 PM logoHedge Funds Are Buying Acceleron Pharma Inc (XLRN) - Insider Monkey (blog) (NASDAQ:XLRN) - December 2 at 8:59 AM
News IconStock Survey: Viewing Levels for Acceleron Pharma Inc. (NASDAQ:XLRN) - Marion Business Daily (NASDAQ:XLRN) - December 1 at 10:08 PM logoAcceleron Pharma to Host Conference Call and... (NASDAQ:XLRN) - November 30 at 12:50 PM logoAcceleron Pharma to Host Conference Call and Webcast to Review Data Presented at the 58th American Society of Hematology Annual Meeting and Exposition (NASDAQ:XLRN) - November 30 at 12:50 PM
News IconHedge Funds Are Buying Acceleron Pharma Inc (XLRN) (NASDAQ:XLRN) - November 30 at 5:33 AM
News IconShares in Focus: Acceleron Pharma Inc. (NASDAQ:XLRN) - Marion Business Daily (NASDAQ:XLRN) - November 29 at 1:26 PM


What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2017?

11 brokerages have issued 12 month price objectives for Acceleron Pharma's shares. Their forecasts range from $39.00 to $63.00. On average, they anticipate Acceleron Pharma's stock price to reach $46.80 in the next year.

When will Acceleron Pharma announce their earnings?

Acceleron Pharma is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:

  • According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (2/10/2017)

  • Credit Suisse Group analysts commented, "We view Mr Dable’s prior role as President of US Pharmaceuticals Bayer and experience in commercial product launches as a strong strategic fit for XLRN’s future commercialization. Further, Mr Dable brings significant collaboration experience from Bayer deals with Genzyme and Regeneron, where he spearheaded ophthalmology business planning and execution. Our conversation with mgmt. indicates Dr. Knopf will stay involved with XLRN in a scientific capacity, after co-founding the company 13 years ago. Mgmt change prepares XLRN for luspatercept co-commercialization: With ph3 trials in MDS and beta-thalassemia ongoing, we see Mr. Dable bringing significant commercial experience to XLRN. We conservatively model luspatercept sales in ESA-resistant and ring sideroblast-positive (RS+) MDS patients (ph3 MEDALIST population) and transfusion dependent beta- thalassemia patients (ph3 BELIEVE population). We model PoS-unadjusted peak year sales ests. of $908M globally in MDS and $1.1B in beta- thalassemia." (9/28/2016)

  • FBR & Co analysts commented, "Acceleron Pharma announced preliminary updated positive data from the ongoing Phase II trials with luspatercept in myelodysplastic syndromes (MDS) and beta- thalassemia that are being presented at the 21st Congress of the EHA. The main takeaway from the beta-thalassemia data, in our opinion, is that 67% (20/30) and 83% (20/24) of transfusion-dependent (TD) patients achieved a ≥33% reduction of transfusion burden from 12 weeks pre-treatment to 12 weeks on treatment in the base and extension study, respectively. In the ongoing extension study, 50% (11/22) of patients with lower-risk MDS who were eligible for transfusion independence (TI) achieved red blood cell transfusion independence (RBC-TI) ≥ 8 weeks (range nine to more than 80 weeks)." (6/13/2016)

Who owns Acceleron Pharma stock?

Acceleron Pharma's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (13.88%), Novo A S (3.29%), State Street Corp (2.50%), Perceptive Advisors LLC (1.64%), Franklin Resources Inc. (1.28%) and Eventide Asset Management LLC (1.14%). Company insiders that own Acceleron Pharma stock include Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire.

Who sold Acceleron Pharma stock? Who is selling Acceleron Pharma stock?

Acceleron Pharma's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Century Capital Management LLC, Franklin Resources Inc. and AQR Capital Management LLC. Company insiders that have sold Acceleron Pharma stock in the last year include Jean George, John D Quisel, John L Knopf, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire.

Who bought Acceleron Pharma stock? Who is buying Acceleron Pharma stock?

Acceleron Pharma's stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Loomis Sayles & Co. L P, Novo A S, Harbourvest Partners LLC, Guggenheim Capital LLC, State Street Corp, Alden Global Capital LLC and Aberdeen Asset Management PLC UK. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski.

How do I buy Acceleron Pharma stock?

Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Acceleron Pharma stock cost?

One share of Acceleron Pharma stock can currently be purchased for approximately $25.20.

Acceleron Pharma (NASDAQ:XLRN) Chart for Thursday, February, 23, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Earnings History Chart

Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Dividend History Chart

Dividend Payments by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Last Updated on 2/23/2017 by Staff